卵巢癌中的免疫检查点阻断
Immune checkpoint blockade in ovarian cancer.
作者信息
Weiss Lukas, Huemer Florian, Mlineritsch Brigitte, Greil Richard
机构信息
3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.
出版信息
Memo. 2016;9:82-84. doi: 10.1007/s12254-016-0267-3. Epub 2016 Jun 2.
Abstract
Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction of anti-tumour T‑cells, in general, these attempts did not translate into clinically significant activity. As has already been shown in other tumour entities, immune checkpoint blockade - mainly antibodies directed against PD-1 and PD-L1 - could possibly become a real "game changer" in ovarian cancer in the future.
摘要
长期以来，肿瘤浸润性T细胞数量增加与卵巢癌较好的预后相关，这使得人们普遍认为T细胞抗肿瘤免疫在这种疾病中具有重要影响。基于这一认识，在过去几年中出现了大量免疫疗法。尽管一些报告能够证明成功诱导了抗肿瘤T细胞，但总体而言，这些尝试并未转化为具有临床意义的活性。正如在其他肿瘤实体中已经显示的那样，免疫检查点阻断——主要是针对PD-1和PD-L1的抗体——未来可能会成为卵巢癌真正的“改变游戏规则者”。
相似文献
1
Immune checkpoint blockade in ovarian cancer.卵巢癌中的免疫检查点阻断
Memo. 2016;9:82-84. doi: 10.1007/s12254-016-0267-3. Epub 2016 Jun 2.
2
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects.卵巢癌中的免疫学与免疫检查点抑制——当前进展
Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1128-1144. doi: 10.1055/a-1475-4335. Epub 2021 Jul 6.
3
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
4
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
5
Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
6
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.在小鼠原位胰腺肿瘤模型中，CD40激动剂抗体对肿瘤微环境的重塑与对PD-L1阻断治疗反应的改善相关。
Oncotarget. 2016 Apr 5;7(14):18508-20. doi: 10.18632/oncotarget.7610.
7
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.抗PD-L1/PD-1免疫疗法在卵巢癌中的应用：基本机制与未来临床应用
Int J Clin Oncol. 2016 Jun;21(3):456-61. doi: 10.1007/s10147-016-0968-y. Epub 2016 Mar 11.
8
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.PD-1/PD-L1 检查点阻断免疫疗法中的预测生物标志物。
Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10.
9
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.抑制免疫检查点用于膀胱癌治疗
Bladder Cancer. 2016 Jan 7;2(1):15-25. doi: 10.3233/BLC-150026.
10
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
引用本文的文献
1
Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer.复发性卵巢癌药物反应和蛋白质生物标志物表达的患者间异质性
Cancers (Basel). 2022 May 3;14(9):2279. doi: 10.3390/cancers14092279.
2
Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.肿瘤浸润淋巴细胞与上皮性卵巢癌激素受体表达模式的临床意义
Int J Mol Sci. 2021 May 27;22(11):5714. doi: 10.3390/ijms22115714.
3
Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy.定量MRI细胞追踪免疫细胞对肿瘤和引流淋巴结的募集情况，以响应抗PD-1和基于DPX的免疫疗法。
Oncoimmunology. 2020 Nov 29;9(1):1851539. doi: 10.1080/2162402X.2020.1851539.
4
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.原发性卵巢癌中原发肿瘤与相应转移灶之间的免疫异质性及对铂类治疗的反应
Cancers (Basel). 2019 Aug 26;11(9):1250. doi: 10.3390/cancers11091250.
5
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.基于 PD-1/PD-L1 通路抑制剂的免疫疗法在卵巢癌治疗中的应用。
Clin Exp Immunol. 2019 Mar;195(3):334-344. doi: 10.1111/cei.13255. Epub 2019 Jan 21.
6
Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.上皮性卵巢癌中的肿瘤浸润性T细胞：预后预测指标及免疫治疗的生物学基础
Gynecol Oncol. 2018 Oct;151(1):1-3. doi: 10.1016/j.ygyno.2018.09.005.
7
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.克服上皮性卵巢癌化疗耐药的新兴治疗策略：小型综述。
Int J Mol Sci. 2017 Oct 18;18(10):2171. doi: 10.3390/ijms18102171.
8
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.上皮性卵巢癌生物标志物检测的建议：西班牙病理学会和西班牙肿瘤内科学会的国家共识声明。
Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16.
9
Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.腺癌中的新兴免疫疗法：聚焦嵌合抗原受体T细胞（CAR-T细胞）
Curr Trends Immunol. 2016;17:95-115.
10
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.程序性死亡-1通路阻断产生协同抗肿瘤作用：在卵巢癌中的联合应用
J Gynecol Oncol. 2017 Sep;28(5):e64. doi: 10.3802/jgo.2017.28.e64. Epub 2017 Jun 5.
本文引用的文献
1
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.抗 PD-1 抗体纳武利尤单抗治疗铂耐药卵巢癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.
2
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.伊匹单抗治疗不可切除或转移性黑色素瘤的II期和III期试验长期生存数据的汇总分析
J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
3
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.CTLA-4 和 PD-1/PD-L1 阻断：黑色素瘤患者具有持久临床获益的新免疫治疗方式。
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
4
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
5
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.肿瘤浸润 T 细胞在卵巢癌中的预后意义：一项荟萃分析。
Gynecol Oncol. 2012 Feb;124(2):192-8. doi: 10.1016/j.ygyno.2011.09.039. Epub 2011 Oct 29.
6
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.程序性细胞死亡蛋白1配体1和肿瘤浸润性CD8 + T淋巴细胞是人类卵巢癌的预后因素。
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. doi: 10.1073/pnas.0611533104. Epub 2007 Feb 21.
7
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.卵巢癌中调节性T细胞的特异性募集促进免疫特权并预示生存率降低。
Nat Med. 2004 Sep;10(9):942-9. doi: 10.1038/nm1093. Epub 2004 Aug 22.
8
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.上皮性卵巢癌中的肿瘤内T细胞、复发及生存情况
N Engl J Med. 2003 Jan 16;348(3):203-13. doi: 10.1056/NEJMoa020177.
Zotero 插件